dexamethasone acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
826 1177-87-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dexamethasone acetate
  • decadronal
  • neofordex
  • Molecular weight: 434.50
  • Formula: C24H31FO6
  • CLOGP: 2.32
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 100.90
  • ALOGS: -4.42
  • ROTB: 4
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.08 mg/mL Bocci G, Oprea TI, Benet LZ
BA (Bioavailability) 81 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.072 Moderate 0.65
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.945 Moderate 0.65
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 46.881 10^-6 cm/s Moderate 0.65
dh-clint Dog hepatocyte intrinsic clearance 15.066 uL/min/10^6 cells Moderate 0.65
dppb Dog plasma protein binding (% unbound) 36.310 % Moderate 0.65
fcs-ppb Fetal calf serum protein binding (% unbound) 44.500 % Moderate 0.65
herg hERG pIC50 4.437 pIC50 Moderate 0.65
hh-clint Human hepatocyte intrinsic clearance 12.677 uL/min/10^6 cells Moderate 0.65
hlm-clint Human liver microsomal intrinsic clearance 31.261 uL/min/mg protein Moderate 0.65
hppb Human plasma protein binding (% unbound) 25.130 % Moderate 0.65
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 11.350 Moderate 0.79
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 5.458 Moderate 0.65
mh-clint Mouse hepatocyte intrinsic clearance 52.966 Moderate 0.65
mppb Mouse plasma protein binding (% unbound) 30.580 Moderate 0.65
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 11.588 Moderate 0.65
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.79
pppb Pig plasma protein binding (% unbound) 36.420 % Moderate 0.65
rat-kpuu-brain Rat brain Kpuu 0.080 % Moderate 0.79
rh-clint Rat hepatocyte intrinsic clearance 76.560 uL/min/10^6 cells Moderate 0.65
rh-fuinc Rat hepatocyte fraction unbound in incubation 76.180 % Moderate 0.65
rppb Rat plasma protein binding (% unbound) 23.440 % Moderate 0.65
solubility-dd Solubility at pH 7.4 in DMSO 368.978 uM Moderate 0.65

Approvals:

DateAgencyCompanyOrphan
Sept. 6, 1973 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutrophil count decreased 482.99 29.67 175 5198 71357 90551717
Platelet count decreased 442.69 29.67 197 5176 136772 90486302
White blood cell count decreased 190.35 29.67 120 5253 166989 90456085
Lymphocyte count decreased 185.80 29.67 72 5301 34978 90588096
Anaemia 168.00 29.67 150 5223 352652 90270422
Fracture 133.68 29.67 50 5323 22026 90601048
Plasma cell myeloma 116.34 29.67 54 5319 40774 90582300
Neuropathy peripheral 74.47 29.67 63 5310 136907 90486167
Tumour lysis syndrome 70.19 29.67 26 5347 11126 90611948
Thrombocytopenia 69.28 29.67 73 5300 208652 90414422
Febrile neutropenia 68.51 29.67 64 5309 158285 90464789
Dementia 63.12 29.67 30 5343 23831 90599243
Neutropenia 61.39 29.67 71 5302 224833 90398241
Myelosuppression 57.12 29.67 37 5336 53554 90569520
Ileus 53.77 29.67 24 5349 16522 90606552
Plasma cell myeloma recurrent 50.77 29.67 16 5357 4212 90618862
Osteonecrosis of jaw 49.20 29.67 30 5343 39073 90584001
Renal impairment 48.25 29.67 44 5329 105377 90517697
Vitiligo 47.51 29.67 13 5360 2097 90620977
Upper respiratory tract inflammation 44.47 29.67 13 5360 2659 90620415
Pyrexia 39.14 29.67 106 5267 660379 89962695
Decreased appetite 36.06 29.67 73 5300 376467 90246607
Drug ineffective 35.65 29.67 19 5354 1384279 89238795
Pneumonia 34.43 29.67 99 5274 637960 89985114
Cardiac failure 33.97 29.67 37 5336 109459 90513615
Marasmus 32.85 29.67 8 5365 815 90622259
Renal disorder 32.81 29.67 23 5350 37836 90585238
Cytopenia 31.65 29.67 17 5356 17432 90605642
Bone marrow failure 31.29 29.67 21 5352 32200 90590874
Cardiac amyloidosis 31.02 29.67 8 5365 1028 90622046
Plasma cell leukaemia 30.14 29.67 8 5365 1150 90621924

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count decreased 253.37 25.39 183 5642 138398 42477112
Neutrophil count decreased 223.83 25.39 127 5698 63288 42552222
Lymphocyte count decreased 96.00 25.39 55 5770 27754 42587756
Pneumonia 94.47 25.39 189 5636 421960 42193550
White blood cell count decreased 89.93 25.39 92 5733 110304 42505206
Anaemia 57.07 25.39 121 5704 280157 42335353
Plasma cell myeloma 56.62 25.39 49 5776 47529 42567981
Dementia 50.00 25.39 30 5795 16450 42599060
Nephritis allergic 46.16 25.39 12 5813 684 42614826
Tumour lysis syndrome 44.11 25.39 31 5794 22200 42593310
Osteonecrosis of jaw 43.57 25.39 29 5796 19020 42596490
Conjunctival irritation 42.68 25.39 8 5817 96 42615414
Neutropenia 41.54 25.39 87 5738 199344 42416166
Bone marrow failure 41.22 25.39 35 5790 33058 42582452
Cardiac failure 35.38 25.39 57 5768 106799 42508711
Myelosuppression 35.19 25.39 35 5790 40426 42575084
Upper respiratory tract inflammation 34.30 25.39 12 5813 1884 42613626
Genital erythema 34.10 25.39 8 5817 297 42615213
Thrombocytopenia 33.92 25.39 78 5747 190201 42425309
Hepatitis B DNA increased 33.54 25.39 9 5816 580 42614930
Drug reaction with eosinophilia and systemic symptoms 32.24 25.39 34 5791 42041 42573469
Liver disorder 32.11 25.39 33 5792 39611 42575899
Mechanical ventilation complication 31.95 25.39 9 5816 695 42614815
Meningioma 31.51 25.39 11 5814 1716 42613794
Renal disorder 30.77 25.39 28 5797 28952 42586558
Interstitial lung disease 30.37 25.39 45 5780 78417 42537093
Fatigue 30.17 25.39 11 5814 435630 42179880
Plasmacytoma 27.67 25.39 13 5812 4351 42611159
Marasmus 25.54 25.39 8 5817 891 42614619

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count decreased 700.20 23.27 381 11193 230062 110347663
Neutrophil count decreased 672.31 23.27 302 11272 120639 110457086
White blood cell count decreased 268.77 23.27 209 11365 229181 110348544
Lymphocyte count decreased 258.32 23.27 124 11450 57119 110520606
Anaemia 204.84 23.27 268 11306 546818 110030907
Plasma cell myeloma 181.71 23.27 101 11473 62835 110514890
Fracture 137.53 23.27 62 11512 24726 110552999
Pneumonia 127.97 23.27 282 11292 876432 109701293
Dementia 108.59 23.27 57 11517 31616 110546109
Tumour lysis syndrome 107.22 23.27 56 11518 30745 110546980
Neuropathy peripheral 101.90 23.27 109 11465 179168 110398557
Neutropenia 97.85 23.27 155 11419 374465 110203260
Thrombocytopenia 93.38 23.27 146 11428 348739 110228986
Osteonecrosis of jaw 89.01 23.27 58 11516 47959 110529766
Myelosuppression 83.09 23.27 73 11501 94267 110483458
Upper respiratory tract inflammation 75.51 23.27 25 11549 4346 110573379
Bone marrow failure 74.74 23.27 56 11518 57792 110519933
Renal disorder 70.92 23.27 51 11523 49428 110528297
Cardiac failure 69.95 23.27 92 11482 187534 110390191
Plasma cell myeloma recurrent 63.86 23.27 25 11549 7017 110570708
Plasmacytoma 59.70 23.27 22 11552 5240 110572485
Pyrexia 57.51 23.27 215 11359 898050 109679675
Cytopenia 57.33 23.27 37 11537 30079 110547646
Marasmus 56.26 23.27 16 11558 1675 110576050
Febrile neutropenia 55.34 23.27 110 11464 316657 110261068
Fatigue 51.48 23.27 32 11542 1215926 109361799
Ileus 49.44 23.27 34 11540 30695 110547030
Hepatic function abnormal 48.41 23.27 53 11521 89242 110488483
Cardiac amyloidosis 48.10 23.27 16 11558 2821 110574904
Liver disorder 45.80 23.27 65 11509 142178 110435547
Nephritis allergic 44.11 23.27 12 11562 1067 110576658
Conjunctival irritation 42.21 23.27 8 11566 136 110577589
Hepatitis B DNA increased 42.02 23.27 11 11563 844 110576881
Cerebral infarction 41.44 23.27 38 11536 51800 110525925
Renal impairment 41.08 23.27 72 11502 188373 110389352
Drug ineffective 41.04 23.27 60 11514 1520480 109057245
Sepsis 40.50 23.27 99 11475 327247 110250478
Headache 40.47 23.27 21 11553 882356 109695369
Plasma cell leukaemia 40.34 23.27 13 11561 2075 110575650
Rash 39.42 23.27 180 11394 820784 109756941
Pain 39.17 23.27 26 11548 954929 109622796
Hyperuricaemia 38.32 23.27 22 11552 14509 110563216
Drug reaction with eosinophilia and systemic symptoms 38.16 23.27 45 11529 82050 110495675
Interstitial lung disease 36.74 23.27 58 11516 139276 110438449
Disseminated intravascular coagulation 36.43 23.27 32 11542 41254 110536471
Spinal compression fracture 36.00 23.27 23 11551 18369 110559356
Vitiligo 35.65 23.27 13 11561 3004 110574721
Genital erythema 35.13 23.27 8 11566 342 110577383
Dyspnoea 34.64 23.27 39 11535 1106833 109470892
Mechanical ventilation complication 33.51 23.27 9 11565 762 110576963
Heat illness 33.27 23.27 9 11565 783 110576942
Hypercalcaemia 33.07 23.27 32 11542 46625 110531100
Myelodysplastic syndrome 32.96 23.27 29 11545 37455 110540270
Hypoalbuminaemia 32.92 23.27 26 11548 28948 110548777
Hypokalaemia 32.59 23.27 64 11510 182384 110395341
Arthralgia 32.25 23.27 21 11553 779611 109798114
Decreased appetite 32.08 23.27 116 11458 475730 110101995
Constipation 31.98 23.27 96 11478 357690 110220035
Haemoglobin decreased 31.57 23.27 76 11498 248651 110329074
Peripheral swelling 31.42 23.27 3 11571 404031 110173694
Colon cancer 30.79 23.27 20 11554 16423 110561302
Delirium 29.94 23.27 52 11522 134973 110442752
Toxicity to various agents 29.57 23.27 7 11567 480548 110097177
Cytokine release syndrome 28.55 23.27 36 11538 70270 110507455
Pain in extremity 28.25 23.27 8 11566 487110 110090615
Blood creatinine increased 27.77 23.27 60 11514 182829 110394896
Meningioma 27.74 23.27 13 11561 5652 110572073
Hyperglycaemia 27.54 23.27 39 11535 85051 110492674
Cataract 26.57 23.27 37 11537 79448 110498277
Swelling 26.27 23.27 3 11571 351038 110226687
Bronchopulmonary aspergillosis 26.05 23.27 23 11551 29840 110547885
Pathological fracture 25.94 23.27 16 11558 12016 110565709
Alopecia 25.20 23.27 4 11570 364749 110212976
Pneumonia bacterial 24.47 23.27 21 11553 26240 110551485
Amyloidosis 24.36 23.27 10 11564 3171 110574554
Compression fracture 24.31 23.27 14 11560 9285 110568440
Gamma-glutamyltransferase increased 24.27 23.27 31 11543 61278 110516447
Enterocolitis 23.70 23.27 18 11556 18931 110558794
Death 23.58 23.27 139 11435 698730 109878995

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000932 Antiemetics
MeSH PA D000970 Antineoplastic Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D018931 Antineoplastic Agents, Hormonal
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33231 antitubercular agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35442 antiparasitic agent
CHEBI has role CHEBI:35472 anti-inflammatory drug
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35718 antifungal agent
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:35845 gout suppressant
CHEBI has role CHEBI:37962 adrenergic agent
CHEBI has role CHEBI:38068 antimalarial
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:49201 anti-ulcer drug
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50671 antithyroid drug
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:50857 anti-allergic agent
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:55324 gastrointestinal drug
CHEBI has role CHEBI:62868 hepatoprotective agent
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:73336 vulnerary
CHEBI has role CHEBI:75835 anti-anaemic agent
CHEBI has role CHEBI:77715 nasal decongestant
CHEBI has role CHEBI:78298 environmental contaminant
CHEBI has role CHEBI:231911 renoprotective agent
CHEBI has role CHEBI:233423 antifibrotic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Multiple myeloma indication 109989006 DOID:9538




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.06 acidic
pKa2 13.41 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST CHEMBL CHEMBL

External reference:

IDSource
4017924 VUID
N0000179099 NUI
D02174 KEGG_DRUG
55812-90-3 SECONDARY_CAS_RN
22690 RXNORM
4017922 VANDF
4017924 VANDF
C0057598 UMLSCUI
CHEBI:4463 CHEBI
DEX PDB_CHEM_ID
CHEMBL1530428 ChEMBL_ID
DB14649 DRUGBANK_ID
C018038 MESH_SUPPLEMENTAL_RECORD_UI
DWN2WN457X UNII
236702 PUBCHEM_CID
4552 MMSL
4553 MMSL
6112 MMSL
6848 MMSL
d00206 MMSL
002174 NDDF
002175 NDDF
109070008 SNOMEDCT_US
372584003 SNOMEDCT_US
7561000 SNOMEDCT_US
C0011777 UMLSCUI
DB01234 DRUGBANK_ID
5743 PUBCHEM_CID
816 INN_ID
D003907 MESH_DESCRIPTOR_UI
CHEBI:41879 CHEBI
DWN2WN457X INXIGHT DRUGS

Pharmaceutical products:

None